- Home
- WPP vs LGND Comparison
WPP vs LGND Comparison
Compare WPP & LGND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | WPP | LGND |
|---|---|---|
| Founded | 1985 | 1987 |
| Country | United Kingdom | United States |
| Employees | 104000 | 68 |
| Industry | Advertising | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.0B | 3.7B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | WPP | LGND |
|---|---|---|
| Price | $18.55 | $198.59 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 2 | 6 |
| Target Price | N/A | ★ $244.83 |
| AVG Volume (30 Days) | ★ 622.3K | 144.2K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 11.22% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $47.71 |
| Revenue Next Year | N/A | $9.77 |
| P/E Ratio | ★ $38.96 | $76.27 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $17.25 | $93.58 |
| 52 Week High | $41.87 | $212.49 |
Technical Indicators
Market Signals| Indicator | WPP | LGND |
|---|---|---|
| Relative Strength Index (RSI) | 43.64 | 59.07 |
| Support Level | $18.41 | $198.52 |
| Resistance Level | $19.38 | $207.72 |
| Average True Range (ATR) | 0.71 | 7.72 |
| MACD | 0.13 | 1.34 |
| Stochastic Oscillator | 47.51 | 85.33 |
Price Performance
Historical ComparisonAbout WPP WPP plc
Headquartered in the United Kingdom, WPP is the world's largest ad holding company based on annual revenue. Its services, which include traditional and digital advertising, public relations, and consulting, are provided worldwide, with over 70% of its revenue coming from more developed regions such as North America, the UK, and Western Europe. WPP is the largest media buying entity in the world.
About LGND Ligand Pharmaceuticals Incorporated
Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.